Abstract
Diabetes mellitus is a group of diseases characterized by hyperglycemia and other metabolic abnormalities resulting from impaired insulin secretion and/or its action at the cellular level.
Similar content being viewed by others
References
https://www.diabetes.org/resources/statistics/statistics-about-diabetes. 20 Apr 2020.
https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. 20 Apr 2020.
American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–31. https://doi.org/10.2337/dc20-S002.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care. 1999;22(1):99–111.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Pharmacologic Approaches to Glycemic Treatments. Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
Melmed S, Polonsky K, Larsen PR, Kronenberg H. Williams textbook of endocrinology. 12th ed. Philadelphia: Elsevier Saunders; 2011.
American Diabetes Association. Diabetes technology: standards of medical Care in Diabetes – 2020. Diabetes Care. 2020;43(Suppl 1):S77–88. https://doi.org/10.2337/dc20-S007.
American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care. 2004;27(Suppl 1):s91–3. https://doi.org/10.2337/diacare.27.2007.S91.
American Diabetes Association. Standards of medical care in diabetes-2020 abridged for primary care providers. Clinical Diabetes. 2020;38(1):10–38.
American Diabetes Association. Management of Diabetes in pregnancy: standards of medical Care in Diabetes – 2019. Diabetes Care. 2019;42(Suppl 1):S165–72.
American Diabetes Association. Lifestyle management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S46–60.
American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103–23.
Kernan W, Viscoli CM, Furie K, Young L, Inzucchi S, Gorman M. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31.
Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.
Gesrtein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double blind, randomized placebo-controlled trial. Lancet. 2019;394:121–30.
Mann J, Orsted D, Brown-Frandsen K, Steven M, Poulter N, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839–48.
Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
Mcmurray J, Solomon S, Inzucchi S, Kober L, Kosiborod M, Martinez F, et al. Dapgliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66–76.
Beigi I, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–9.
American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135–51.
Bhatt D, Steg G, Miller M, Brinton E, Jacobson T, Ketchum S. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
Kitabchi A, Umpierrez G, Miles J, Fisher J. Hyperglycemic crisis in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–43.
Diabetes Care in the Hospital: Standards of Medical Care in Diabetes 2020. Diabetes care 2020. Diabetes Care. 2020;43(Suppl 1):S193–202.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media LLC
About this entry
Cite this entry
El Asmar, N., Arafah, B.M., Smith, C.K. (2020). Diabetes Mellitus. In: Paulman, P., Taylor, R.B., Paulman, A.A., Nasir, L.S. (eds) Family Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0779-3_186-1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0779-3_186-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0779-3
Online ISBN: 978-1-4939-0779-3
eBook Packages: Springer Reference MedicineReference Module Medicine